Neuraxis, INC financial data

Symbol
NRXS on NYSE
Industry
Electromedical & Electrotherapeutic Apparatus
Location
11611 N. Meridian St, Suite 330, Carmel, Indiana
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q4 2024 - May 20, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 10.2 %
Quick Ratio 0.62 %
Debt-to-equity -127 %
Return On Equity 373 % +261%
Return On Assets -1.38K %
Operating Margin -330 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.65M shares
Common Stock, Shares, Outstanding 6.59M shares
Common Stock, Value, Issued 6.6K USD
Weighted Average Number of Shares Outstanding, Basic 6.55M shares +227%
Weighted Average Number of Shares Outstanding, Diluted 6.55M shares +227%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.46M USD -8.37%
Revenue from Contract with Customer, Excluding Assessed Tax 2.3M USD -19.7%
Research and Development Expense 158K USD -66.8%
General and Administrative Expense 9.17M USD +56.5%
Operating Income (Loss) -7.6M USD -104%
Net Income (Loss) Attributable to Parent -14.6M USD -152%
Earnings Per Share, Basic -3.64 USD/shares +72.9%
Earnings Per Share, Diluted -3.64 USD/shares +72.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 81.8K USD
Accounts Receivable, after Allowance for Credit Loss, Current 90.5K USD
Inventory, Net 20.2K USD
Assets, Current 408K USD
Property, Plant and Equipment, Net 95.2K USD
Operating Lease, Right-of-Use Asset 337K USD
Assets 946K USD
Accounts Payable, Current 1.24M USD
Accrued Liabilities, Current 816K USD
Liabilities, Current 3.82M USD
Operating Lease, Liability, Noncurrent 314K USD
Liabilities 4.13M USD
Retained Earnings (Accumulated Deficit) -50.7M USD
Stockholders' Equity Attributable to Parent -3.18M USD +58.9%
Liabilities and Equity 946K USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.33M USD -114%
Net Cash Provided by (Used in) Financing Activities 1.35M USD +220%
Net Cash Provided by (Used in) Investing Activities -14.7K USD -93.5%
Common Stock, Shares Authorized 100M shares
Common Stock, Shares, Issued 6.59M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.19K USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 16.9K USD -52.9%
Deferred Tax Assets, Valuation Allowance 10.9M USD +41.9%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Operating Lease, Liability 350K USD
Depreciation 30.2K USD -2.2%
Payments to Acquire Property, Plant, and Equipment 14.7K USD +93.5%
Lessee, Operating Lease, Liability, to be Paid 498K USD
Property, Plant and Equipment, Gross 451K USD
Operating Lease, Liability, Current 35.8K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 115K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 111K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 148K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 86.9K USD
Deferred Tax Assets, Operating Loss Carryforwards 6.57M USD +98.6%
Preferred Stock, Shares Authorized 1.12M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 89K USD
Additional Paid in Capital 47.5M USD
Amortization of Intangible Assets 10.5K USD +68.8%
Depreciation, Depletion and Amortization 10.7K USD +9.02%
Interest Expense 341K USD -83.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares